By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



863 Mitten Road
Suite 100C
Burlingame  California  94010-1303  U.S.A.
Phone: 650-931-6236 ext 502 Fax: 650-931-6235


Apexigen is a biopharmaceutical product development company advancing a pipeline of novel product candidates with the potential to address life-threatening and difficult to treat diseases. The company’s proprietary technology platform enables the discovery and development of superior antibody product candidates that are able to impact previously inaccessible disease mechanisms.

While many companies are working to develop antibody therapies based on mouse- or human-derived antibody technologies, Apexigen is pioneering a movement into therapeutics based on rabbit-derived humanized monoclonal antibodies as a means of providing therapeutic benefits that have not been achieved through the use of other technologies.

Several blockbuster antibody drugs have been developed with existing mouse and human antibody technologies and display libraries. However, the development of the next generation of antibody-based drugs will require capabilities that exceed those of current technologies in order to bind rare or intractable antigen epitopes and to exert novel effects on disease processes. The key to these next generation therapeutics lies in harnessing the inherent advantages of rabbit antibodies, which have been used successfully in research settings for decades. These advantages are the result of rabbit’s ability to generate a much greater diversity of unique high quality antibodies - with high affinity, high specificity and which bind unique antigen epitopes. These attributes enable the discovery of antibodies that are capable of targeting previously unreachable disease mechanisms.

The company’s proprietary platform technology has allowed Apexigen to build a strong and broad pipeline of seven unique humanized monoclonal antibody programs spanning indications including oncology, inflammatory disease and ophthalmology. Of these seven candidates, four are currently the subject of development partnerships with leading life science companies.

Apexigen’s most advanced internal development program, APX005, is a humanized monoclonal antibody targeting the CD40 protein for the treatment of cancers. Apexigen believes that CD40-induced activation of the immune system by APX005 has the potential to treat a variety of difficult to treat cancers, such as pancreatic cancer, and has exhibited potent anti-tumor effects in animal models.

Collaboration is one of Apexigen’s strengths. At present, seven corporate collaborations are in place, representing both product development collaborations and antibody technology collaborations. Through the building of successful collaborations, Apexigen is able to develop a broad base of antibody products and promote wider use of its antibody technology platform.

Key Statistics

Ownership: Private

Web Site: Apexigen
Employees: n/a


Company News
Neon Therapeutics And Apexigen Announce Immuno-Oncology Clinical Trial Collaboration 7/25/2017 7:46:20 AM
Apexigen Announces First Patient Dosed In Phase Ib/II Clinical Trial Of APX005M In Combination With Opdivo (Nivolumab) In Advanced Solid Tumors 7/17/2017 6:29:22 AM
Bristol-Myers Squibb (BMY) And Apexigen Announce Clinical Collaboration To Evaluate Opdivo (Nivolumab) In Combination With APX005M In Advanced Solid Tumors 4/11/2017 6:17:27 AM
Phase II/II Clinical Trial Of Apexigen's APX005M In Combination With Pembrolizumab (Keytruda) Opens For Metastatic Melanoma Patients 3/21/2017 6:30:24 AM
Apexigen Receives Clinical Development Milestone Payment Under Collaboration Agreement 3/16/2017 9:14:00 AM
Apexigen Receives Clinical Development Milestone Payment Under Collaboration Agreement 3/16/2017 6:51:24 AM
Apexigen To Present Data On Its Novel Immuno-Oncology Program APX005M At Upcoming Cancer Conferences 4/13/2016 7:24:13 AM
Apexigen Presents Positive Data For APX005M In Podium Presentation At Immune Checkpoint Inhibitors (ICI) Europe 11/17/2015 7:27:35 AM
Apexigen Presents Preclinical Data From Novel Immuno-Oncology Candidate APX005M At SITC 2015 Meeting 11/6/2015 6:19:41 AM
3SBio Inc. (SSRX) Acquires Global Rights to Bay Area Apexigen’s Anti-TNF mAb 6/22/2015 7:15:01 AM